LRC junior research group
New HKI junior research group conducts research on synthetic biology
Natural active compounds of artificial cells.
To find new compounds for drug development is becoming increasingly difficult - known drug producers have been already been exploited and new search options are lacking. Scientists at the Leibniz Research Cluster now want to break new ground by combining biological knowledge with engineering skills: cells are to be replaced by cell-free systems that produce promising agents efficiently.
Vito Valiante will lead the newly established research group at the Leibniz Institute for Natural Product Research and Infection Biology - Hans Knöll Institute. The 37-year-old Italian sees the mold Aspergillus fumigatus as a great starting point for hisresearch. “We will select interesting factors from the fungus and we are trying to produce them artificially. This knowledge will be passed on to our partners.”
Four additional Leibniz institutes will work on the system ‘cell’ in order to imitate it and use it to find new active compounds.